Johnson & Johnson (JNJ) remains a stalwart in the healthcare sector, focusing on innovative medicines and medical devices after strategically separating its Consumer Health division. With a stable overall score, it continues to be a reliable long-term investment, although it faces typical industry risks such as regulatory changes and market competition.
The company's overall performance is reflected in its fundamental scores, showcasing a solid financial position with room for improvement in some areas such as debt management.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 3 | |
| Price to Book | 1 |
Historical ratings provide insight into the consistency of Johnson & Johnson's fundamental strengths and areas of potential improvement over time.
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | PE | PB |
|---|---|---|---|---|---|---|---|
| 04/10/2026 | 3 | 4 | 5 | 5 | 1 | 3 | 1 |
| N/A | 0 | 4 | 5 | 5 | 1 | 3 | 1 |
Analysts provide price targets which project a potential upside based on market conditions, with a consensus leaning towards a Buy recommendation.
| High | Low | Median | Consensus |
|---|---|---|---|
| 267 | 190 | 220 | 229.67 |
The sentiment among analysts reflects a generally positive outlook with a majority recommending Buy, though a few suggest a more cautious approach.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 20 | |
| Hold | 17 | |
| Sell | 3 | |
| Strong Sell | 0 |
Johnson & Johnson exhibits steady growth with a strong presence in innovative healthcare solutions. While facing challenges from debt management and market competition, its robust ROE and asset efficiency reinforce its long-term viability. Analysts remain optimistic, with consensus leaning towards a Buy recommendation, making JNJ an attractive option for growth-oriented investors seeking exposure in the healthcare sector. Nevertheless, potential investors should consider the inherent risks in global healthcare markets.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.